UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

Metastatic Breast Cancer-Specific Prognostic Tool

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Behavioral: Patients and Caregivers Qualitative Interview

First Posted Date: 2022-10-10

Last Posted Date: 2024-03-04

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT05574478

Locations: 🇺🇸
Terri Eubanks, Chapel Hill, North Carolina, United States

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Polatuzumab vedotin (PV)
Drug: Rituximab
Drug: Hyaluronidase
Drug: Gemcitabine
Drug: Cisplatin
Drug: Dexamethasone
Drug: GCSF

First Posted Date: 2022-08-11

Last Posted Date: 2024-03-05

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 44

Registration Number: NCT05498220

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Phase 2

Recruiting

Conditions: Complex Atypical Hyperplasia
Endometrial Cancer

Interventions: Drug: 18F-fluorofuranylnorprogesterone PET / MRI

First Posted Date: 2022-08-01

Last Posted Date: 2024-06-06

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT05483023

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)

Phase 2

Recruiting

Conditions: Quality of Life
Breast Cancer

Interventions: Radiation: Accelerated Partial Breast Irradiation (APBI)
Drug: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene

First Posted Date: 2022-07-25

Last Posted Date: 2024-04-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 90

Registration Number: NCT05472792

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

Not Applicable

Recruiting

Conditions: CIN2
Cervical Cancer
CIN3

Interventions: Other: Urine HPV testing
Other: Self-collected cervicovaginal specimen
Other: Provider-collected cervical samples

First Posted Date: 2022-06-10

Last Posted Date: 2024-06-25

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 300

Registration Number: NCT05413798

Locations: 🇿🇦
Clinical HIV Research Unit Temba Lethu Wing Helen Joseph Hospital, Westdene, Johannesburg, South Africa

The Families Addressing Cancer Together Intervention for Parents With Cancer

Not Applicable

Completed

Conditions: Cancer
Parent-Child Relations
Neoplasms
Parenting
Communication
Parents

Interventions: Behavioral: FACT

First Posted Date: 2022-05-17

Last Posted Date: 2024-05-23

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 47

Registration Number: NCT05377749

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States

Pembrolizumab Plus Olaparib in LA-HNSCC

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Biological: Pembrolizumab
Drug: Olaparib
Drug: Cisplatin
Radiation: IMRT (intensity modulated radiation therapy)

First Posted Date: 2022-05-09

Last Posted Date: 2024-02-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT05366166

Locations: 🇺🇸
UNC Lineberger, Chapel Hill, North Carolina, United States
🇺🇸
University of Louisville, Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸
Medical University of South Carolina (MUSC), Charleston, South Carolina, United States

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Phase 1

Recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: CAR.B7-H3T cells infusion

First Posted Date: 2022-05-09

Last Posted Date: 2024-10-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT05366179

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa

Phase 1

Completed

Conditions: CIN 2/3
HIV Infections

Interventions: Drug: Intravaginal 5-Fluorouracil (5-FU)

First Posted Date: 2022-05-05

Last Posted Date: 2024-08-23

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT05362955

Locations: 🇰🇪
Lumumba Sub-County Hospital KEMRI- Research Care Training Program (RCTP) Building, Kisumu, Kenya

Pre-Implementation Study of Improving Thoracic Surgical Care Using Electronic Patient-Reported Outcomes (ePROS)

Completed

Conditions: Thoracic Surgery

Interventions: Behavioral: Patient-reported outcomes monitoring

First Posted Date: 2022-04-05

Last Posted Date: 2023-12-20

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT05311670

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy